Evidence map›Paper›PMID 28748913›Full record

ArticleActa pharmacologica Sinica2018

D-chiro-inositol effectively attenuates cholestasis in bile duct ligated rats by improving bile acid secretion and attenuating oxidative stress.

Shuang-Shuang Zhao, Na-Ren Li, Wu-Li Zhao, Hong Liu, Mao-Xu Ge, Yi-Xuan Zhang, Long-Yin Zhao, Xue-Fu You, Hong-Wei He, Rong-Guang Shao

Open access · bronzeAbstract read
In one paragraph

Article in Acta pharmacologica Sinica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Antioxidant and hepatoprotective activities ofResearch in pharmaceutical sciences · 2024
    Article
  4. Article
  5. Article
  6. The Protective Effects ofBioMed research international · 2022
    Article
  7. Article
  8. Article
  9. Antioxidant and Anti-Inflammatory Effects ofEvidence-based complementary and alternative medicine : eCAM · 2021
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Shuang-Shuang ZhaoKey Laboratory of Biotechnology of Antibiotics, the National Health and Family Planning Commission (NHFPC); Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Na-Ren LiKey Laboratory of Biotechnology of Antibiotics, the National Health and Family Planning Commission (NHFPC); Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Wu-Li ZhaoKey Laboratory of Biotechnology of Antibiotics, the National Health and Family Planning Commission (NHFPC); Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Hong LiuKey Laboratory of Biotechnology of Antibiotics, the National Health and Family Planning Commission (NHFPC); Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Mao-Xu GeKey Laboratory of Biotechnology of Antibiotics, the National Health and Family Planning Commission (NHFPC); Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Yi-Xuan ZhangKey Laboratory of Biotechnology of Antibiotics, the National Health and Family Planning Commission (NHFPC); Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Long-Yin ZhaoBeijing Jince-Spring Medical Technology Co, Ltd, Beijing 100102, China.
Xue-Fu YouDepartment of Pharmacology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Hong-Wei HeKey Laboratory of Biotechnology of Antibiotics, the National Health and Family Planning Commission (NHFPC); Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Rong-Guang ShaoKey Laboratory of Biotechnology of Antibiotics, the National Health and Family Planning Commission (NHFPC); Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
National Health and Family Planning Commission · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholestatic liver diseases are important causes of liver cirrhosis and liver transplantation, but few drugs are available for treatment. D-chiro-inositol (DCI), an isomer of inositol found in many Leguminosae plants and in animal viscera, is used clinically for the treatment of polycystic ovary syndrome (PCOS) and diabetes mellitus. In this study, we investigated whether DCI exerted an anti-cholestatic effect and its underlying mechanisms. A cholestatic rat model was established via bile duct ligation (BDL). After the surgery, the rats were given DCI (150 mg·kg

Indexed as

Alanine TransaminaseAnimalsAntigens, CDAntigens, Differentiation, MyelomonocyticAspartate AminotransferasesATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily B, Member 11Bile Acids and SaltsBile DuctsCD68 MoleculeCholestasisDisease Models, AnimalGene ExpressionInositolLigationLiverAbcb11 protein, ratAbcc2 protein, ratAlanine TransaminaseAntigens, CDAntigens, Differentiation, MyelomonocyticAspartate AminotransferasesATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily B, Member 11Bile Acids and SaltsCD68 MoleculeCD68 protein, ratInositolNF-kappa BProtective AgentsSuperoxide Dismutase

Identifiers

PMID28748913
PMCPMC5800478
OpenAlexW2742020541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.